Clinical trials: Relapsed and Refractory Acute Myeloid Leukemia (RR-AML), open to volunteers
- Condition Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.